Search
Filter Results
Displaying 21–30 of 194 for “x-linked”
-
Oct 6, 2016
Embrace Your Exceptions: A Mantra for Understanding Retinal-Disease Inheritance
The complex and elusive nature of these conditions can also extend to the way they are passed down in families, making diagnosis and prognosis quite challenging.
-
Dec 6, 2023
Recording Available: Foundation Insights Forum – November 30, 2023
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on November 30, 2023.
-
Funded Grants and Awards for Fiscal Year 2019 (July 1, 2018-June 30, 2019)
-
Aug 16, 2019
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Jan 9, 2018
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
May 2, 2024
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
The XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Nov 10, 2023
The Eye on the Cure Podcast from the Foundation Fighting Blindness provides science information, news, and insights from the world of vision and retinal diseases. The podcasts are hosted by Ben Shaberman, vice president, science communications, and often include conversations with guests from the research and vision communities.
-
Aug 28, 2023
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
The AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
May 2, 2023
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023